Archives
-
LPS Shields Macrophages from Chemotherapy via System Xc− and
2026-08-04
This study reveals that lipopolysaccharide (LPS) confers selective protection to macrophages against antitumor drugs by upregulating system Xc− and implicating ABCC1-mediated drug transport. These mechanistic insights advance understanding of immune preservation during chemotherapy and suggest strategies for reducing off-target cytotoxicity in cancer therapy.
-
Dinaciclib (SCH727965): Applied Workflows in Cancer and Boun
2026-08-01
Dinaciclib (SCH727965) stands out as a potent, multi-target CDK inhibitor enabling precise cell cycle arrest and apoptosis induction across cancer and developmental models. This article translates foundational boundary maintenance research into actionable protocols and troubleshooting strategies for advanced oncology and tissue organization studies.
-
Porcupine Inhibition for Sclerosteosis: Mechanisms and Thera
2026-07-31
This study identifies pharmacological porcupine (PORCN) inhibition as a promising approach to limit excessive bone formation in severe sclerosteosis, an ultra-rare high bone mass disorder. By targeting Wnt signaling with LGK974 in Sost-deficient models, the research demonstrates significant reductions in pathological bone overgrowth, providing a foundation for non-surgical treatment strategies.
-
Rapid Microwave Heating Preserves Lactoferrin Structure and
2026-07-31
This study demonstrates that rapid microwave (MW) heating, rather than dielectric effects, is key to preserving the structural integrity and biological function of lactoferrin during thermal processing. These findings offer practical guidance for optimizing industrial dairy pasteurization to retain the health-promoting properties of lactoferrin.
-
Cell Counting Kit-8 Plus: Precision in Dehydrogenase Activit
2026-07-30
Explore how Cell Counting Kit-8 Plus advances tetrazolium salt assays with enhanced sensitivity and rapid cell proliferation analysis. Discover its unique suitability for mechanistic studies in inflammation and drug screening.
-
RBMS1 Loss Enables PD-L1 Blockade in Triple-Negative Breast
2026-07-29
This study identifies RBMS1 as a novel regulator of PD-L1 stability in triple-negative breast cancer (TNBC). Loss of RBMS1 enhances anti-tumor immunity and sensitizes TNBC tumors to immune checkpoint blockade, providing a promising new target for improving immunotherapy outcomes.
-
SKA2 Drives Gastric Cancer Progression via Glutathione Metab
2026-07-27
This study uncovers how SKA2 overexpression in gastric cancer modulates glutathione metabolism, promoting tumor growth and poor prognosis. By elucidating the SKA2-SLC6A9-GSH-ROS axis, the research highlights a critical metabolic vulnerability that could inform future therapeutic strategies.
-
Resazurin Cell Viability Assay Kit: Precision in ROS-Driven
2026-07-27
Explore how the Resazurin Cell Viability Assay Kit enables ultra-sensitive, non-toxic quantification of cell viability, with unique insights into ROS-mediated mechanisms in oncology and drug discovery. This article clarifies advanced protocol choices and directly links resazurin-based detection to practical research breakthroughs.
-
HAUS1 Expression and Immune Microenvironment in HCC: New Ins
2026-07-26
This study systematically investigates HAUS1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma (HCC), revealing its strong association with immune cell infiltration and poor patient outcomes. The findings highlight mechanisms by which HAUS1 drives tumor progression and suggest new avenues for targeted therapy and immunomodulation in HCC.
-
MLKL Polymerization Drives Lysosomal Rupture in Necroptosis
2026-07-24
This study elucidates how polymerized MLKL induces lysosomal membrane permeabilization (LMP), releasing cathepsins and driving necroptotic cell death. The mechanistic link between MLKL polymerization, LMP, and cathepsin-mediated cytotoxicity advances our understanding of regulated necrosis and opens new investigative avenues for protease inhibition strategies.
-
Trypsin: The Serine Protease Powering Advanced Cell Workflow
2026-07-23
Trypsin (BA5744) from APExBIO unlocks high-precision cell culture, membrane fusion, and proteomics workflows through its unique specificity and solubility profile. This guide translates the latest mechanistic insights and practical troubleshooting tips into actionable protocols for cell biologists and translational researchers.
-
Ciprofloxacin in Nanotheranostics: Mechanisms and Research A
2026-07-23
Explore the advanced applications and mechanisms of Ciprofloxacin, a leading fluoroquinolone antibiotic, in cutting-edge nanotheranostic research. This in-depth analysis reveals unique insights for antimicrobial resistance and cancer models, setting it apart from standard product overviews.
-
Nanoparticle-mRNA Therapy Reverses Trastuzumab Resistance in
2026-07-22
This study introduces a pH-responsive nanoparticle platform for systemic mRNA delivery that overcomes trastuzumab resistance in HER2-positive breast cancer. By restoring PTEN expression, the approach blocks PI3K/Akt signaling and suppresses tumor growth, offering a promising strategy for resistant cancer therapy.
-
Isoprinosine (SKU C4417): Reliable Immunomodulation in Viral
2026-07-22
This article addresses core laboratory challenges in viral infection models and immunotherapy research, focusing on the scientific and workflow advantages of Isoprinosine (SKU C4417). By examining real-world scenarios, we demonstrate how Isoprinosine supports reproducible, sensitive, and safe assay development, anchored with literature and practical protocols. APExBIO’s Isoprinosine is evaluated for researchers seeking consistent results in cell viability, proliferation, and cytotoxicity studies.
-
Elesclomol-Induced Copper Influx Modulates ER Stress and PCK
2026-07-21
This study uncovers how elesclomol promotes copper influx in lung adenocarcinoma (LUAD) cells, activating ER stress and upregulating PCK2, which suppresses cancer progression. The findings establish the ES–ER stress–PCK2 axis as a promising therapeutic target for LUAD and highlight the metabolic vulnerabilities exploitable in cancer therapy.
446 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page